** AstraZeneca +1%, second-top riser on FTSE 100 in volume
** Liberum upgrades to "buy" v "hold" - with stock down 8pct YTD, trading around 5-mth lows, risk/reward going into arich seam of catalysts is now strongly to the upside
** Four major immuno-oncology readouts in 2017 (incl.MYSTIC) plus key data on Acalabrutinib, Lynparza and Tagrissothere is 25-30% upside to Liberum's FV if positive
** European Healthcare among the region's worst performersin the last three months, with the sector having been at thefore of concerns surrounding US election outcome (Liberum:sector trade-off overdone, Trump a major positive)
** Old Mutual Global Investors' Simon Murphy has been buyingHealthcare into weakness (GSK and AZN)
** Of MYSTIC, due 2017, PM said recently analysts expectshares up or down 10-15% on the day (positive outcome meanspossible $5 bln sales over next 5-10 yrs for a co that has $25bln revenues, per PM)
** Healthcare +0.6% on Friday, one of only twoEuropean sectors in positive territory (Food & Beverages also up0.6%)
** Swiss biotech group Actelion top performer,+9.5%, on potential takeover by Johnson & Johnson (Bloomberg report)
(RM: tricia.wright1.thomsonreuters.com@reuters.net)